Substituted benzamides containing azaspiro rings as upregulators of Apolipoprotein A-I transcription

Molecules

Volumn 17, Issue 6, 2012, Pages 7379-7386

  Du, Yu ^a   Yang, Yuan ^a   Jiang, Wei ^a   Wang, Li ^a   Jia, Xiao Jian ^a   Si, Shu Yi ^a   Chen, Xiao Fang ^a   Hong, Bin ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Apolipoprotein A I; Atherosclerosis; Structure activity relationship; Transcriptional upregulator

Indexed keywords

APOLIPOPROTEIN A1; BENZAMIDE DERIVATIVE; SPIRO COMPOUND;

ARTICLE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MOLECULAR LIBRARY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; UPREGULATION;

APOLIPOPROTEIN A-I; BENZAMIDES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; SMALL MOLECULE LIBRARIES; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84862985299     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17067379     Document Type: Article

References (17)

1. Brewer, H. B. High-density lipoproteins: A new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 387-391.
2. Rader, D. J. Molecular regulation of HDL metabolism and function: Implications for novel therapies. J. Clin. Invest. 2006, 116, 3090-3100. (Pubitemid 44878620)
3. Boden, W. E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the veterans Affairs High-density lipoprotein intervention trial. Am. J. Cardiol. 2000, 86, 19L-22L.
4. Duffy, D.; Rader, D. J. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006, 113, 1140-1150.
5. Tall, A. R. Plasma high density lipoproteins: Metabolism and relationship to atherogenesis. J. Clin. Invest. 1990, 86, 379-384. (Pubitemid 20271868)
6. Shah, P. K. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr. Opin. Cardiol. 2010, 25, 603-608.
7. Rubin, E. M.; Krauss, R. M.; Spangler, E. A.; Verstuyft, J. G.; Clift, S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991, 353, 265-267. (Pubitemid 21896769)
8. Tangirala, R. K.; Tsukamoto, K.; Chun, S. H.; Usher, D.; Puré, E.; Rader, D. J. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999, 100, 1816-1822. (Pubitemid 29498389)
9. de Goma, E. M.; Rader, D. J. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 2011, 8, 266-277.
10. Nicholls, S. J.; Gordon, A.; Johansson, J.; Wolski, K.; Ballantyne, C. M.; Kastelein, J. J.; Taylor, A.; Borgman, M.; Nissen, S. E. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease: A randomized controlled trial. J. Am. Coll. Cardiol. 2011, 57, 1111-1119.
11. Du, Y.; Wang, L.; Wang, L. F.; Si, S. Y.; Yang, Y.; Hong, B. Establishment of a high-throughput screening model for identifying up-regulator of human Apo A-I expression. Chin. Med. Biotechnol. 2011, 6, 178-183.
12. Vu-Dac, N.; Chopin-Delannoy, S.; Gervois, P.; Bonnelye, E.; Martin, G.; Fruchart, J. C.; Laudet, V.; Staels, B. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem. 1998, 273, 25713-25720. (Pubitemid 28475794)
13. Zhang, L. H.; Kamanna, V. S.; Ganji, S. H.; Xiong, X. M.; Kashyap, M. L. Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells. J. Lipid. Res. 2010, 51, 2211-2222.
14. Zhang, X. K.; Lehmann, J.; Hoffmann, B.; Dawson, M. I.; Cameron, J.; Graupner, G.; Hermann, T.; Tran, P.; Pfahl, M. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 1992, 358, 587-591.
15. Wong Norman, C. W. Use of resveratrol to regulate expression of apolipoprotein A1. United States Patent Application Publication, 20040033480A1, 19 February 2004.
16. McNeill, E. RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. Curr. Opin. Investig. Drugs 2010, 11, 357-364.
17. Jiang, W.; Si, S. Y.; Chen, X. P.; Wang, L.; Zhuang, X. L.; Zou, J.; Chen, H. S.; Cao L. X.; Feng, H.; Chen, L. Development and application of microbial natural products database. J. Chin. Antibiot. 2006, 36, 119-121.